nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—ABCG2—Dactinomycin—sarcoma	0.108	0.289	CbGbCtD
Cladribine—ABCG2—Mitoxantrone—sarcoma	0.0963	0.259	CbGbCtD
Cladribine—ABCG2—Vincristine—sarcoma	0.0663	0.178	CbGbCtD
Cladribine—ABCG2—Etoposide—sarcoma	0.0607	0.163	CbGbCtD
Cladribine—ABCG2—Doxorubicin—sarcoma	0.0414	0.111	CbGbCtD
Cladribine—RRM1—larynx—sarcoma	0.00751	0.0379	CbGeAlD
Cladribine—POLE4—embryo—sarcoma	0.00655	0.0331	CbGeAlD
Cladribine—NR5A1—Ovarian Infertility Genes—GJA4—sarcoma	0.00613	0.0781	CbGpPWpGaD
Cladribine—POLE2—embryo—sarcoma	0.00573	0.0289	CbGeAlD
Cladribine—POLE4—skin of body—sarcoma	0.00509	0.0257	CbGeAlD
Cladribine—POLE3—mammary gland—sarcoma	0.00466	0.0235	CbGeAlD
Cladribine—Adenosine monophosphate—CREB1—sarcoma	0.00426	0.712	CrCbGaD
Cladribine—POLE—mammary gland—sarcoma	0.00355	0.0179	CbGeAlD
Cladribine—RRM2B—myometrium—sarcoma	0.0035	0.0177	CbGeAlD
Cladribine—POLE2—tendon—sarcoma	0.00338	0.0171	CbGeAlD
Cladribine—POLE3—myometrium—sarcoma	0.00331	0.0167	CbGeAlD
Cladribine—POLE2—bone marrow—sarcoma	0.00328	0.0166	CbGeAlD
Cladribine—PNP—hematopoietic system—sarcoma	0.00324	0.0163	CbGeAlD
Cladribine—POLE3—embryo—sarcoma	0.00318	0.0161	CbGeAlD
Cladribine—RRM2B—seminal vesicle—sarcoma	0.00316	0.016	CbGeAlD
Cladribine—POLA1—mammary gland—sarcoma	0.00306	0.0155	CbGeAlD
Cladribine—POLE4—liver—sarcoma	0.00303	0.0153	CbGeAlD
Cladribine—RRM2B—hematopoietic system—sarcoma	0.003	0.0152	CbGeAlD
Cladribine—POLE3—seminal vesicle—sarcoma	0.00299	0.0151	CbGeAlD
Cladribine—RRM2—mammary gland—sarcoma	0.00293	0.0148	CbGeAlD
Cladribine—RRM2B—connective tissue—sarcoma	0.00289	0.0146	CbGeAlD
Cladribine—POLE3—hematopoietic system—sarcoma	0.00284	0.0143	CbGeAlD
Cladribine—POLE2—testis—sarcoma	0.0028	0.0142	CbGeAlD
Cladribine—NR5A1—hematopoietic system—sarcoma	0.00275	0.0139	CbGeAlD
Cladribine—POLE2—liver—sarcoma	0.00265	0.0134	CbGeAlD
Cladribine—POLE—myometrium—sarcoma	0.00252	0.0127	CbGeAlD
Cladribine—RRM2B—Direct p53 effectors—COL18A1—sarcoma	0.00252	0.0321	CbGpPWpGaD
Cladribine—PNP—uterus—sarcoma	0.00244	0.0123	CbGeAlD
Cladribine—RRM1—mammary gland—sarcoma	0.00243	0.0123	CbGeAlD
Cladribine—POLE—embryo—sarcoma	0.00243	0.0122	CbGeAlD
Cladribine—RRM2B—cardiac atrium—sarcoma	0.00228	0.0115	CbGeAlD
Cladribine—POLE—seminal vesicle—sarcoma	0.00228	0.0115	CbGeAlD
Cladribine—PNP—lymphoid tissue—sarcoma	0.00228	0.0115	CbGeAlD
Cladribine—RRM1—Fluoropyrimidine Activity—SMUG1—sarcoma	0.00218	0.0278	CbGpPWpGaD
Cladribine—POLA1—myometrium—sarcoma	0.00217	0.011	CbGeAlD
Cladribine—POLE—hematopoietic system—sarcoma	0.00217	0.0109	CbGeAlD
Cladribine—POLE3—cardiac atrium—sarcoma	0.00216	0.0109	CbGeAlD
Cladribine—RRM2—myometrium—sarcoma	0.00208	0.0105	CbGeAlD
Cladribine—PNP—bone marrow—sarcoma	0.00207	0.0105	CbGeAlD
Cladribine—POLE2—lymph node—sarcoma	0.00203	0.0103	CbGeAlD
Cladribine—POLE3—lymphoid tissue—sarcoma	0.002	0.0101	CbGeAlD
Cladribine—RRM2—embryo—sarcoma	0.002	0.0101	CbGeAlD
Cladribine—RRM2B—tendon—sarcoma	0.00199	0.01	CbGeAlD
Cladribine—POLA1—seminal vesicle—sarcoma	0.00196	0.00992	CbGeAlD
Cladribine—NR5A1—lymphoid tissue—sarcoma	0.00194	0.00978	CbGeAlD
Cladribine—RRM2B—bone marrow—sarcoma	0.00193	0.00972	CbGeAlD
Cladribine—POLE3—tendon—sarcoma	0.00188	0.00949	CbGeAlD
Cladribine—POLA1—hematopoietic system—sarcoma	0.00187	0.00943	CbGeAlD
Cladribine—POLE3—bone marrow—sarcoma	0.00182	0.00919	CbGeAlD
Cladribine—RRM2—Fluoropyrimidine Activity—SMUG1—sarcoma	0.0018	0.0229	CbGpPWpGaD
Cladribine—RRM2—hematopoietic system—sarcoma	0.00178	0.00901	CbGeAlD
Cladribine—RRM1—myometrium—sarcoma	0.00173	0.00871	CbGeAlD
Cladribine—Adenosine monophosphate—SRC—sarcoma	0.00172	0.288	CrCbGaD
Cladribine—SLC28A3—bone marrow—sarcoma	0.0017	0.0086	CbGeAlD
Cladribine—PNP—liver—sarcoma	0.00168	0.00846	CbGeAlD
Cladribine—POLE2—Chromosome Maintenance—NPM1—sarcoma	0.00166	0.0211	CbGpPWpGaD
Cladribine—RRM2B—testis—sarcoma	0.00165	0.00831	CbGeAlD
Cladribine—POLE2—S Phase—STAG1—sarcoma	0.00161	0.0206	CbGpPWpGaD
Cladribine—RRM1—seminal vesicle—sarcoma	0.00156	0.00787	CbGeAlD
Cladribine—RRM2B—liver—sarcoma	0.00156	0.00786	CbGeAlD
Cladribine—POLE3—testis—sarcoma	0.00156	0.00786	CbGeAlD
Cladribine—RRM2—skin of body—sarcoma	0.00155	0.00783	CbGeAlD
Cladribine—POLE—lymphoid tissue—sarcoma	0.00152	0.0077	CbGeAlD
Cladribine—NR5A1—testis—sarcoma	0.00151	0.00761	CbGeAlD
Cladribine—RRM1—hematopoietic system—sarcoma	0.00148	0.00748	CbGeAlD
Cladribine—POLE3—liver—sarcoma	0.00147	0.00743	CbGeAlD
Cladribine—POLE—tendon—sarcoma	0.00143	0.00724	CbGeAlD
Cladribine—POLE—bone marrow—sarcoma	0.00139	0.00701	CbGeAlD
Cladribine—RRM2B—DNA Damage Response—CREB1—sarcoma	0.00138	0.0175	CbGpPWpGaD
Cladribine—POLE2—Teniposide—Etoposide—sarcoma	0.00137	0.147	CbGdCrCtD
Cladribine—RRM2—uterus—sarcoma	0.00135	0.0068	CbGeAlD
Cladribine—DCK—myometrium—sarcoma	0.00134	0.00677	CbGeAlD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—CREB1—sarcoma	0.00133	0.0169	CbGpPWpGaD
Cladribine—RRM1—smooth muscle tissue—sarcoma	0.0013	0.00659	CbGeAlD
Cladribine—DCK—embryo—sarcoma	0.00129	0.00651	CbGeAlD
Cladribine—RRM1—skin of body—sarcoma	0.00129	0.0065	CbGeAlD
Cladribine—RRM2—lymphoid tissue—sarcoma	0.00126	0.00634	CbGeAlD
Cladribine—POLA1—tendon—sarcoma	0.00124	0.00624	CbGeAlD
Cladribine—DCK—seminal vesicle—sarcoma	0.00121	0.00611	CbGeAlD
Cladribine—POLA1—bone marrow—sarcoma	0.0012	0.00604	CbGeAlD
Cladribine—RRM2B—lymph node—sarcoma	0.00119	0.00602	CbGeAlD
Cladribine—POLE—testis—sarcoma	0.00119	0.00599	CbGeAlD
Cladribine—RRM2—tendon—sarcoma	0.00118	0.00596	CbGeAlD
Cladribine—DCK—hematopoietic system—sarcoma	0.00115	0.00581	CbGeAlD
Cladribine—RRM2—bone marrow—sarcoma	0.00114	0.00577	CbGeAlD
Cladribine—RRM2B—DNA Damage Response—MDM2—sarcoma	0.00114	0.0145	CbGpPWpGaD
Cladribine—POLE3—lymph node—sarcoma	0.00113	0.00569	CbGeAlD
Cladribine—RRM1—cardiac atrium—sarcoma	0.00112	0.00568	CbGeAlD
Cladribine—POLE—liver—sarcoma	0.00112	0.00567	CbGeAlD
Cladribine—RRM1—uterus—sarcoma	0.00112	0.00565	CbGeAlD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—MDM2—sarcoma	0.0011	0.014	CbGpPWpGaD
Cladribine—RRM2—Vinorelbine—Vincristine—sarcoma	0.00109	0.117	CbGdCrCtD
Cladribine—POLE—Chromosome Maintenance—NPM1—sarcoma	0.00107	0.0136	CbGpPWpGaD
Cladribine—RRM1—lymphoid tissue—sarcoma	0.00104	0.00527	CbGeAlD
Cladribine—POLE—S Phase—STAG1—sarcoma	0.00104	0.0132	CbGpPWpGaD
Cladribine—POLA1—Vinblastine—Vincristine—sarcoma	0.00103	0.111	CbGdCrCtD
Cladribine—POLA1—testis—sarcoma	0.00102	0.00517	CbGeAlD
Cladribine—POLE2—DNA Repair—SMUG1—sarcoma	0.001	0.0128	CbGpPWpGaD
Cladribine—RRM2B—DNA Damage Response—CCND1—sarcoma	0.000992	0.0126	CbGpPWpGaD
Cladribine—RRM1—tendon—sarcoma	0.000981	0.00495	CbGeAlD
Cladribine—RRM2—testis—sarcoma	0.000977	0.00494	CbGeAlD
Cladribine—POLA1—liver—sarcoma	0.000967	0.00488	CbGeAlD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—CCND1—sarcoma	0.000958	0.0122	CbGpPWpGaD
Cladribine—RRM1—bone marrow—sarcoma	0.00095	0.0048	CbGeAlD
Cladribine—RRM2—liver—sarcoma	0.000924	0.00467	CbGeAlD
Cladribine—DCK—cardiac atrium—sarcoma	0.000874	0.00441	CbGeAlD
Cladribine—DCK—uterus—sarcoma	0.000869	0.00439	CbGeAlD
Cladribine—POLE—lymph node—sarcoma	0.00086	0.00434	CbGeAlD
Cladribine—POLE2—G1 to S cell cycle control—CREB1—sarcoma	0.000841	0.0107	CbGpPWpGaD
Cladribine—RRM1—testis—sarcoma	0.000812	0.0041	CbGeAlD
Cladribine—DCK—lymphoid tissue—sarcoma	0.00081	0.00409	CbGeAlD
Cladribine—NR5A1—Developmental Biology—MYOG—sarcoma	0.000807	0.0103	CbGpPWpGaD
Cladribine—RRM2B—DNA Damage Response—MYC—sarcoma	0.000795	0.0101	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—MYC—sarcoma	0.000768	0.0098	CbGpPWpGaD
Cladribine—RRM1—liver—sarcoma	0.000768	0.00388	CbGeAlD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000766	0.00976	CbGpPWpGaD
Cladribine—POLA1—Chromosome Maintenance—NPM1—sarcoma	0.000762	0.00971	CbGpPWpGaD
Cladribine—DCK—tendon—sarcoma	0.000762	0.00385	CbGeAlD
Cladribine—ABCG2—myometrium—sarcoma	0.000748	0.00378	CbGeAlD
Cladribine—POLA1—lymph node—sarcoma	0.000741	0.00374	CbGeAlD
Cladribine—POLA1—S Phase—STAG1—sarcoma	0.00074	0.00944	CbGpPWpGaD
Cladribine—DCK—bone marrow—sarcoma	0.000738	0.00373	CbGeAlD
Cladribine—POLE2—Mitotic M-M/G1 phases—STAG1—sarcoma	0.000734	0.00935	CbGpPWpGaD
Cladribine—ABCG2—HIF-2-alpha transcription factor network—FLT1—sarcoma	0.000726	0.00926	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—MMP2—sarcoma	0.000719	0.00916	CbGpPWpGaD
Cladribine—POLE2—Daunorubicin—Epirubicin—sarcoma	0.000716	0.0768	CbGdCrCtD
Cladribine—POLE2—Doxorubicin—Epirubicin—sarcoma	0.000716	0.0768	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Epirubicin—sarcoma	0.000716	0.0768	CbGdCrCtD
Cladribine—RRM2—lymph node—sarcoma	0.000708	0.00358	CbGeAlD
Cladribine—POLE2—G1 to S cell cycle control—MDM2—sarcoma	0.000695	0.00887	CbGpPWpGaD
Cladribine—ABCG2—seminal vesicle—sarcoma	0.000675	0.00341	CbGeAlD
Cladribine—ABCG2—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000673	0.00858	CbGpPWpGaD
Cladribine—POLE2—Idarubicin—Doxorubicin—sarcoma	0.000662	0.0711	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Doxorubicin—sarcoma	0.000662	0.0711	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Doxorubicin—sarcoma	0.000662	0.0711	CbGdCrCtD
Cladribine—RRM2B—DNA Damage Response—TP53—sarcoma	0.000653	0.00833	CbGpPWpGaD
Cladribine—POLE—DNA Repair—SMUG1—sarcoma	0.000645	0.00822	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—MDM2—sarcoma	0.000639	0.00814	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—TP53—sarcoma	0.000631	0.00804	CbGpPWpGaD
Cladribine—DCK—testis—sarcoma	0.000631	0.00318	CbGeAlD
Cladribine—NR5A1—Developmental Biology—EZR—sarcoma	0.000611	0.00779	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—CCND1—sarcoma	0.000606	0.00772	CbGpPWpGaD
Cladribine—DCK—liver—sarcoma	0.000596	0.00301	CbGeAlD
Cladribine—RRM1—lymph node—sarcoma	0.000589	0.00297	CbGeAlD
Cladribine—RRM1—Fluoropyrimidine Activity—TP53—sarcoma	0.00058	0.00739	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000571	0.00728	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	0.000571	0.00728	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—JUN—sarcoma	0.000555	0.00708	CbGpPWpGaD
Cladribine—PNP—Daunorubicin—Epirubicin—sarcoma	0.000552	0.0593	CbGdCrCtD
Cladribine—POLE2—Cell Cycle, Mitotic—STAG1—sarcoma	0.000549	0.007	CbGpPWpGaD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000542	0.00691	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—CREB1—sarcoma	0.000542	0.00691	CbGpPWpGaD
Cladribine—PNP—Daunorubicin—Doxorubicin—sarcoma	0.000511	0.0549	CbGdCrCtD
Cladribine—SLC22A1—liver—sarcoma	0.000508	0.00257	CbGeAlD
Cladribine—NR5A1—Developmental Biology—MYOD1—sarcoma	0.000498	0.00635	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	0.000497	0.00634	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—STAG1—sarcoma	0.000491	0.00626	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—MYC—sarcoma	0.000486	0.00619	CbGpPWpGaD
Cladribine—ABCG2—uterus—sarcoma	0.000485	0.00245	CbGeAlD
Cladribine—RRM2—Fluoropyrimidine Activity—TP53—sarcoma	0.000478	0.00609	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—STAG1—sarcoma	0.000473	0.00603	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	0.000465	0.00593	CbGpPWpGaD
Cladribine—DCK—lymph node—sarcoma	0.000457	0.00231	CbGeAlD
Cladribine—POLE—G1 to S cell cycle control—MDM2—sarcoma	0.000448	0.00571	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—EGFR—sarcoma	0.000437	0.00557	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000431	0.0055	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—NPM1—sarcoma	0.000421	0.00537	CbGpPWpGaD
Cladribine—ABCG2—HIF-2-alpha transcription factor network—KDR—sarcoma	0.000419	0.00534	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—FUS—sarcoma	0.000413	0.00526	CbGpPWpGaD
Cladribine—ABCG2—bone marrow—sarcoma	0.000412	0.00208	CbGeAlD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000406	0.00518	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	0.000405	0.00517	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000403	0.00514	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—TP53—sarcoma	0.000399	0.00509	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—MYC—sarcoma	0.000399	0.00509	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—CCND1—sarcoma	0.00039	0.00498	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	0.000383	0.00489	CbGpPWpGaD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.000377	0.00481	CbGpPWpGaD
Cladribine—POLE2—S Phase—CCND1—sarcoma	0.000377	0.00481	CbGpPWpGaD
Cladribine—RRM1—E2F transcription factor network—MYC—sarcoma	0.000374	0.00477	CbGpPWpGaD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000372	0.00474	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—STAG1—sarcoma	0.000368	0.0047	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	0.000368	0.00469	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—TP53—sarcoma	0.000367	0.00467	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—PTPRC—sarcoma	0.00036	0.00459	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	0.000358	0.00457	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—STAG1—sarcoma	0.000354	0.00451	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—PLCG1—sarcoma	0.000353	0.0045	CbGpPWpGaD
Cladribine—ABCG2—testis—sarcoma	0.000352	0.00178	CbGeAlD
Cladribine—POLE2—Mitotic G1-G1/S phases—CCND1—sarcoma	0.00035	0.00446	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—STAG1—sarcoma	0.000337	0.0043	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	0.000334	0.00426	CbGpPWpGaD
Cladribine—POLE2—G1/S Transition—MYC—sarcoma	0.000333	0.00425	CbGpPWpGaD
Cladribine—ABCG2—liver—sarcoma	0.000333	0.00168	CbGeAlD
Cladribine—RRM2—Cell Cycle—STAG1—sarcoma	0.000329	0.0042	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—TP53—sarcoma	0.000328	0.00418	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—MYC—sarcoma	0.000325	0.00415	CbGpPWpGaD
Cladribine—DCK—Doxorubicin—Epirubicin—sarcoma	0.000323	0.0346	CbGdCrCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	0.000321	0.00409	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—STAG1—sarcoma	0.000316	0.00403	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—MYC—sarcoma	0.000313	0.00399	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	0.000312	0.00398	CbGpPWpGaD
Cladribine—RRM2—E2F transcription factor network—MYC—sarcoma	0.000308	0.00393	CbGpPWpGaD
Cladribine—POLE2—S Phase—MYC—sarcoma	0.000302	0.00386	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.0003	0.00382	CbGpPWpGaD
Cladribine—DCK—Epirubicin—Doxorubicin—sarcoma	0.000298	0.032	CbGdCrCtD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	0.000288	0.00367	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—NPM1—sarcoma	0.000283	0.0036	CbGpPWpGaD
Cladribine—Dyspnoea—Mitoxantrone—sarcoma	0.000281	0.000838	CcSEcCtD
Cladribine—POLE2—Mitotic G1-G1/S phases—MYC—sarcoma	0.000281	0.00358	CbGpPWpGaD
Cladribine—Cough—Etoposide—sarcoma	0.000281	0.000836	CcSEcCtD
Cladribine—Somnolence—Mitoxantrone—sarcoma	0.000281	0.000835	CcSEcCtD
Cladribine—Gastrointestinal disorder—Vincristine—sarcoma	0.00028	0.000833	CcSEcCtD
Cladribine—Fatigue—Vincristine—sarcoma	0.000279	0.000832	CcSEcCtD
Cladribine—Constipation—Vincristine—sarcoma	0.000277	0.000825	CcSEcCtD
Cladribine—Pain—Vincristine—sarcoma	0.000277	0.000825	CcSEcCtD
Cladribine—Pain in extremity—Doxorubicin—sarcoma	0.000277	0.000825	CcSEcCtD
Cladribine—Decreased appetite—Mitoxantrone—sarcoma	0.000274	0.000817	CcSEcCtD
Cladribine—Chest pain—Etoposide—sarcoma	0.000274	0.000815	CcSEcCtD
Cladribine—Fatigue—Mitoxantrone—sarcoma	0.000272	0.00081	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000272	0.00081	CcSEcCtD
Cladribine—POLE—Cell Cycle—NPM1—sarcoma	0.000271	0.00346	CbGpPWpGaD
Cladribine—Discomfort—Etoposide—sarcoma	0.000271	0.000805	CcSEcCtD
Cladribine—Constipation—Mitoxantrone—sarcoma	0.00027	0.000803	CcSEcCtD
Cladribine—Pain—Mitoxantrone—sarcoma	0.00027	0.000803	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.00027	0.000803	CcSEcCtD
Cladribine—Hypersensitivity—Thiotepa—sarcoma	0.000269	0.000802	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—MYC—sarcoma	0.000268	0.00341	CbGpPWpGaD
Cladribine—Hypersensitivity—Dactinomycin—sarcoma	0.000267	0.000796	CcSEcCtD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—sarcoma	0.000267	0.0034	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Vincristine—sarcoma	0.000265	0.000789	CcSEcCtD
Cladribine—Confusional state—Etoposide—sarcoma	0.000265	0.000788	CcSEcCtD
Cladribine—Muscular weakness—Epirubicin—sarcoma	0.000264	0.000786	CcSEcCtD
Cladribine—Asthenia—Thiotepa—sarcoma	0.000262	0.000781	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	0.000262	0.00334	CbGpPWpGaD
Cladribine—Infection—Etoposide—sarcoma	0.000261	0.000776	CcSEcCtD
Cladribine—Ataxia—Doxorubicin—sarcoma	0.000261	0.000775	CcSEcCtD
Cladribine—Asthenia—Dactinomycin—sarcoma	0.00026	0.000775	CcSEcCtD
Cladribine—Feeling abnormal—Mitoxantrone—sarcoma	0.00026	0.000774	CcSEcCtD
Cladribine—Pruritus—Thiotepa—sarcoma	0.000259	0.00077	CcSEcCtD
Cladribine—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000258	0.000768	CcSEcCtD
Cladribine—POLE—G1 to S cell cycle control—TP53—sarcoma	0.000257	0.00328	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—MYC—sarcoma	0.000257	0.00328	CbGpPWpGaD
Cladribine—Thrombocytopenia—Etoposide—sarcoma	0.000257	0.000765	CcSEcCtD
Cladribine—RRM2B—Metabolism—ENO2—sarcoma	0.000256	0.00327	CbGpPWpGaD
Cladribine—Tachycardia—Etoposide—sarcoma	0.000256	0.000763	CcSEcCtD
Cladribine—Eosinophilia—Epirubicin—sarcoma	0.000256	0.000763	CcSEcCtD
Cladribine—Body temperature increased—Vincristine—sarcoma	0.000256	0.000763	CcSEcCtD
Cladribine—Abdominal pain—Vincristine—sarcoma	0.000256	0.000763	CcSEcCtD
Cladribine—ABCG2—lymph node—sarcoma	0.000255	0.00129	CbGeAlD
Cladribine—Skin disorder—Etoposide—sarcoma	0.000255	0.000759	CcSEcCtD
Cladribine—RRM2B—Metabolism—HBA1—sarcoma	0.000255	0.00325	CbGpPWpGaD
Cladribine—Hyperhidrosis—Etoposide—sarcoma	0.000254	0.000755	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—STAG1—sarcoma	0.000252	0.00321	CbGpPWpGaD
Cladribine—Urticaria—Mitoxantrone—sarcoma	0.000251	0.000746	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—MYC—sarcoma	0.00025	0.00319	CbGpPWpGaD
Cladribine—Anorexia—Etoposide—sarcoma	0.00025	0.000745	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—FOXO1—sarcoma	0.00025	0.00319	CbGpPWpGaD
Cladribine—Diarrhoea—Thiotepa—sarcoma	0.00025	0.000744	CcSEcCtD
Cladribine—Abdominal pain—Mitoxantrone—sarcoma	0.00025	0.000743	CcSEcCtD
Cladribine—Body temperature increased—Mitoxantrone—sarcoma	0.00025	0.000743	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000249	0.000743	CcSEcCtD
Cladribine—Diarrhoea—Dactinomycin—sarcoma	0.000248	0.000739	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000248	0.00316	CbGpPWpGaD
Cladribine—Pancytopenia—Epirubicin—sarcoma	0.000246	0.000732	CcSEcCtD
Cladribine—Hypotension—Etoposide—sarcoma	0.000245	0.00073	CcSEcCtD
Cladribine—Muscular weakness—Doxorubicin—sarcoma	0.000244	0.000727	CcSEcCtD
Cladribine—POLE—S Phase—CCND1—sarcoma	0.000243	0.0031	CbGpPWpGaD
Cladribine—Neutropenia—Epirubicin—sarcoma	0.000242	0.00072	CcSEcCtD
Cladribine—Dizziness—Thiotepa—sarcoma	0.000242	0.000719	CcSEcCtD
Cladribine—Upper respiratory tract infection—Epirubicin—sarcoma	0.000241	0.000716	CcSEcCtD
Cladribine—Hypersensitivity—Vincristine—sarcoma	0.000239	0.000711	CcSEcCtD
Cladribine—Eosinophilia—Doxorubicin—sarcoma	0.000237	0.000706	CcSEcCtD
Cladribine—Paraesthesia—Etoposide—sarcoma	0.000236	0.000702	CcSEcCtD
Cladribine—RRM2—Mitotic G1-G1/S phases—CCND1—sarcoma	0.000235	0.003	CbGpPWpGaD
Cladribine—Dyspnoea—Etoposide—sarcoma	0.000234	0.000697	CcSEcCtD
Cladribine—Somnolence—Etoposide—sarcoma	0.000233	0.000695	CcSEcCtD
Cladribine—Hypersensitivity—Mitoxantrone—sarcoma	0.000233	0.000692	CcSEcCtD
Cladribine—Asthenia—Vincristine—sarcoma	0.000233	0.000692	CcSEcCtD
Cladribine—Vomiting—Thiotepa—sarcoma	0.000232	0.000692	CcSEcCtD
Cladribine—Pneumonia—Epirubicin—sarcoma	0.000232	0.000691	CcSEcCtD
Cladribine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—sarcoma	0.000231	0.00294	CbGpPWpGaD
Cladribine—Infestation NOS—Epirubicin—sarcoma	0.000231	0.000687	CcSEcCtD
Cladribine—Infestation—Epirubicin—sarcoma	0.000231	0.000687	CcSEcCtD
Cladribine—Vomiting—Dactinomycin—sarcoma	0.000231	0.000687	CcSEcCtD
Cladribine—Rash—Thiotepa—sarcoma	0.00023	0.000686	CcSEcCtD
Cladribine—Dermatitis—Thiotepa—sarcoma	0.00023	0.000685	CcSEcCtD
Cladribine—Headache—Thiotepa—sarcoma	0.000229	0.000682	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000229	0.00292	CbGpPWpGaD
Cladribine—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000229	0.000681	CcSEcCtD
Cladribine—Rash—Dactinomycin—sarcoma	0.000229	0.000681	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	0.000228	0.00291	CbGpPWpGaD
Cladribine—Decreased appetite—Etoposide—sarcoma	0.000228	0.000679	CcSEcCtD
Cladribine—Pancytopenia—Doxorubicin—sarcoma	0.000227	0.000677	CcSEcCtD
Cladribine—Renal failure—Epirubicin—sarcoma	0.000227	0.000675	CcSEcCtD
Cladribine—Gastrointestinal disorder—Etoposide—sarcoma	0.000227	0.000675	CcSEcCtD
Cladribine—Asthenia—Mitoxantrone—sarcoma	0.000226	0.000674	CcSEcCtD
Cladribine—Fatigue—Etoposide—sarcoma	0.000226	0.000674	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—CCND1—sarcoma	0.000226	0.00288	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—STAG1—sarcoma	0.000225	0.00287	CbGpPWpGaD
Cladribine—Pain—Etoposide—sarcoma	0.000225	0.000668	CcSEcCtD
Cladribine—Constipation—Etoposide—sarcoma	0.000225	0.000668	CcSEcCtD
Cladribine—Conjunctivitis—Epirubicin—sarcoma	0.000224	0.000668	CcSEcCtD
Cladribine—Urinary tract infection—Epirubicin—sarcoma	0.000224	0.000668	CcSEcCtD
Cladribine—Neutropenia—Doxorubicin—sarcoma	0.000224	0.000667	CcSEcCtD
Cladribine—RRM2—G1/S Transition—MYC—sarcoma	0.000224	0.00285	CbGpPWpGaD
Cladribine—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000223	0.000662	CcSEcCtD
Cladribine—PNP—Metabolism—ENO2—sarcoma	0.000222	0.00284	CbGpPWpGaD
Cladribine—Diarrhoea—Vincristine—sarcoma	0.000222	0.00066	CcSEcCtD
Cladribine—PNP—Metabolism—HBA1—sarcoma	0.000221	0.00282	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—sarcoma	0.00022	0.0028	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Epirubicin—sarcoma	0.000218	0.00065	CcSEcCtD
Cladribine—Epistaxis—Epirubicin—sarcoma	0.000218	0.000648	CcSEcCtD
Cladribine—RRM2B—Metabolism—PLCG1—sarcoma	0.000218	0.00277	CbGpPWpGaD
Cladribine—Nausea—Thiotepa—sarcoma	0.000217	0.000646	CcSEcCtD
Cladribine—Feeling abnormal—Etoposide—sarcoma	0.000216	0.000644	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000216	0.00276	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—CREB1—sarcoma	0.000216	0.00276	CbGpPWpGaD
Cladribine—Diarrhoea—Mitoxantrone—sarcoma	0.000216	0.000643	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000216	0.00275	CbGpPWpGaD
Cladribine—Nausea—Dactinomycin—sarcoma	0.000215	0.000641	CcSEcCtD
Cladribine—Pneumonia—Doxorubicin—sarcoma	0.000215	0.000639	CcSEcCtD
Cladribine—Gastrointestinal pain—Etoposide—sarcoma	0.000215	0.000639	CcSEcCtD
Cladribine—POLE—G1/S Transition—MYC—sarcoma	0.000215	0.00274	CbGpPWpGaD
Cladribine—Dizziness—Vincristine—sarcoma	0.000214	0.000638	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000214	0.00273	CbGpPWpGaD
Cladribine—Infestation NOS—Doxorubicin—sarcoma	0.000214	0.000636	CcSEcCtD
Cladribine—Infestation—Doxorubicin—sarcoma	0.000214	0.000636	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000212	0.00063	CcSEcCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—sarcoma	0.000211	0.00269	CbGpPWpGaD
Cladribine—POLA1—E2F transcription factor network—MYC—sarcoma	0.000211	0.00269	CbGpPWpGaD
Cladribine—Renal failure—Doxorubicin—sarcoma	0.00021	0.000625	CcSEcCtD
Cladribine—Urticaria—Etoposide—sarcoma	0.000209	0.000621	CcSEcCtD
Cladribine—Haemoglobin—Epirubicin—sarcoma	0.000208	0.00062	CcSEcCtD
Cladribine—Body temperature increased—Etoposide—sarcoma	0.000208	0.000618	CcSEcCtD
Cladribine—Abdominal pain—Etoposide—sarcoma	0.000208	0.000618	CcSEcCtD
Cladribine—Conjunctivitis—Doxorubicin—sarcoma	0.000208	0.000618	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—sarcoma	0.000208	0.000618	CcSEcCtD
Cladribine—Haemorrhage—Epirubicin—sarcoma	0.000207	0.000617	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—KDR—sarcoma	0.000207	0.00264	CbGpPWpGaD
Cladribine—Vomiting—Vincristine—sarcoma	0.000206	0.000613	CcSEcCtD
Cladribine—Pharyngitis—Epirubicin—sarcoma	0.000206	0.000612	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—sarcoma	0.000206	0.00262	CbGpPWpGaD
Cladribine—Urinary tract disorder—Epirubicin—sarcoma	0.000205	0.000609	CcSEcCtD
Cladribine—Rash—Vincristine—sarcoma	0.000204	0.000608	CcSEcCtD
Cladribine—Dermatitis—Vincristine—sarcoma	0.000204	0.000608	CcSEcCtD
Cladribine—Oedema peripheral—Epirubicin—sarcoma	0.000204	0.000607	CcSEcCtD
Cladribine—Connective tissue disorder—Epirubicin—sarcoma	0.000204	0.000606	CcSEcCtD
Cladribine—Urethral disorder—Epirubicin—sarcoma	0.000203	0.000604	CcSEcCtD
Cladribine—Headache—Vincristine—sarcoma	0.000203	0.000604	CcSEcCtD
Cladribine—Hepatobiliary disease—Doxorubicin—sarcoma	0.000202	0.000601	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—sarcoma	0.000201	0.000599	CcSEcCtD
Cladribine—Vomiting—Mitoxantrone—sarcoma	0.000201	0.000597	CcSEcCtD
Cladribine—Rash—Mitoxantrone—sarcoma	0.000199	0.000592	CcSEcCtD
Cladribine—Dermatitis—Mitoxantrone—sarcoma	0.000199	0.000592	CcSEcCtD
Cladribine—Headache—Mitoxantrone—sarcoma	0.000198	0.000589	CcSEcCtD
Cladribine—Erythema multiforme—Epirubicin—sarcoma	0.000196	0.000583	CcSEcCtD
Cladribine—POLE—S Phase—MYC—sarcoma	0.000195	0.00248	CbGpPWpGaD
Cladribine—Eye disorder—Epirubicin—sarcoma	0.000194	0.000576	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000193	0.00247	CbGpPWpGaD
Cladribine—Hypersensitivity—Etoposide—sarcoma	0.000193	0.000576	CcSEcCtD
Cladribine—POLA1—Cell Cycle—NPM1—sarcoma	0.000193	0.00246	CbGpPWpGaD
Cladribine—Haemoglobin—Doxorubicin—sarcoma	0.000193	0.000573	CcSEcCtD
Cladribine—Nausea—Vincristine—sarcoma	0.000193	0.000573	CcSEcCtD
Cladribine—Cardiac disorder—Epirubicin—sarcoma	0.000192	0.000572	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—sarcoma	0.000192	0.000571	CcSEcCtD
Cladribine—Pharyngitis—Doxorubicin—sarcoma	0.00019	0.000566	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—sarcoma	0.000189	0.000563	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—sarcoma	0.000189	0.000562	CcSEcCtD
Cladribine—PNP—Metabolism—PLCG1—sarcoma	0.000189	0.00241	CbGpPWpGaD
Cladribine—RRM2—Mitotic G1-G1/S phases—MYC—sarcoma	0.000188	0.0024	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000188	0.0024	CbGpPWpGaD
Cladribine—Asthenia—Etoposide—sarcoma	0.000188	0.000561	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—sarcoma	0.000188	0.000561	CcSEcCtD
Cladribine—Angiopathy—Epirubicin—sarcoma	0.000188	0.000559	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—sarcoma	0.000188	0.000559	CcSEcCtD
Cladribine—Nausea—Mitoxantrone—sarcoma	0.000187	0.000558	CcSEcCtD
Cladribine—Immune system disorder—Epirubicin—sarcoma	0.000187	0.000557	CcSEcCtD
Cladribine—Mediastinal disorder—Epirubicin—sarcoma	0.000187	0.000556	CcSEcCtD
Cladribine—Chills—Epirubicin—sarcoma	0.000186	0.000553	CcSEcCtD
Cladribine—Pruritus—Etoposide—sarcoma	0.000186	0.000553	CcSEcCtD
Cladribine—Arrhythmia—Epirubicin—sarcoma	0.000185	0.000551	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—MYC—sarcoma	0.000183	0.00234	CbGpPWpGaD
Cladribine—Alopecia—Epirubicin—sarcoma	0.000183	0.000545	CcSEcCtD
Cladribine—Mental disorder—Epirubicin—sarcoma	0.000181	0.00054	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—CREB1—sarcoma	0.000181	0.00231	CbGpPWpGaD
Cladribine—Erythema multiforme—Doxorubicin—sarcoma	0.000181	0.000539	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—MYC—sarcoma	0.000181	0.00231	CbGpPWpGaD
Cladribine—Malnutrition—Epirubicin—sarcoma	0.00018	0.000537	CcSEcCtD
Cladribine—Erythema—Epirubicin—sarcoma	0.00018	0.000537	CcSEcCtD
Cladribine—Diarrhoea—Etoposide—sarcoma	0.00018	0.000535	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—sarcoma	0.000179	0.000533	CcSEcCtD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—sarcoma	0.000179	0.00228	CbGpPWpGaD
Cladribine—Cardiac disorder—Doxorubicin—sarcoma	0.000178	0.000529	CcSEcCtD
Cladribine—Flatulence—Epirubicin—sarcoma	0.000178	0.000529	CcSEcCtD
Cladribine—Back pain—Epirubicin—sarcoma	0.000174	0.000519	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—sarcoma	0.000174	0.000518	CcSEcCtD
Cladribine—Dizziness—Etoposide—sarcoma	0.000174	0.000517	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000173	0.00221	CbGpPWpGaD
Cladribine—Immune system disorder—Doxorubicin—sarcoma	0.000173	0.000515	CcSEcCtD
Cladribine—POLA1—S Phase—CCND1—sarcoma	0.000173	0.00221	CbGpPWpGaD
Cladribine—Mediastinal disorder—Doxorubicin—sarcoma	0.000173	0.000514	CcSEcCtD
Cladribine—Chills—Doxorubicin—sarcoma	0.000172	0.000512	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—sarcoma	0.000171	0.00051	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.00017	0.00216	CbGpPWpGaD
Cladribine—Alopecia—Doxorubicin—sarcoma	0.000169	0.000504	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000169	0.00215	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MMP2—sarcoma	0.000169	0.00215	CbGpPWpGaD
Cladribine—Mental disorder—Doxorubicin—sarcoma	0.000168	0.0005	CcSEcCtD
Cladribine—Ill-defined disorder—Epirubicin—sarcoma	0.000167	0.000498	CcSEcCtD
Cladribine—Vomiting—Etoposide—sarcoma	0.000167	0.000497	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—sarcoma	0.000167	0.000497	CcSEcCtD
Cladribine—Erythema—Doxorubicin—sarcoma	0.000167	0.000497	CcSEcCtD
Cladribine—Anaemia—Epirubicin—sarcoma	0.000167	0.000496	CcSEcCtD
Cladribine—Rash—Etoposide—sarcoma	0.000166	0.000493	CcSEcCtD
Cladribine—Dermatitis—Etoposide—sarcoma	0.000165	0.000492	CcSEcCtD
Cladribine—Headache—Etoposide—sarcoma	0.000164	0.00049	CcSEcCtD
Cladribine—Flatulence—Doxorubicin—sarcoma	0.000164	0.000489	CcSEcCtD
Cladribine—Malaise—Epirubicin—sarcoma	0.000163	0.000484	CcSEcCtD
Cladribine—Back pain—Doxorubicin—sarcoma	0.000161	0.00048	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—CCND1—sarcoma	0.000161	0.00205	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.00016	0.00204	CbGpPWpGaD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	0.000159	0.00202	CbGpPWpGaD
Cladribine—Cough—Epirubicin—sarcoma	0.000157	0.000468	CcSEcCtD
Cladribine—Nausea—Etoposide—sarcoma	0.000156	0.000464	CcSEcCtD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—JUN—sarcoma	0.000155	0.00198	CbGpPWpGaD
Cladribine—Ill-defined disorder—Doxorubicin—sarcoma	0.000155	0.000461	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—sarcoma	0.000154	0.000459	CcSEcCtD
Cladribine—Chest pain—Epirubicin—sarcoma	0.000154	0.000457	CcSEcCtD
Cladribine—Arthralgia—Epirubicin—sarcoma	0.000154	0.000457	CcSEcCtD
Cladribine—Myalgia—Epirubicin—sarcoma	0.000154	0.000457	CcSEcCtD
Cladribine—Anxiety—Epirubicin—sarcoma	0.000153	0.000455	CcSEcCtD
Cladribine—POLA1—G1/S Transition—MYC—sarcoma	0.000153	0.00195	CbGpPWpGaD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000152	0.000454	CcSEcCtD
Cladribine—Discomfort—Epirubicin—sarcoma	0.000152	0.000451	CcSEcCtD
Cladribine—Malaise—Doxorubicin—sarcoma	0.00015	0.000448	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—sarcoma	0.00015	0.00192	CbGpPWpGaD
Cladribine—Confusional state—Epirubicin—sarcoma	0.000148	0.000442	CcSEcCtD
Cladribine—Oedema—Epirubicin—sarcoma	0.000147	0.000438	CcSEcCtD
Cladribine—Infection—Epirubicin—sarcoma	0.000146	0.000435	CcSEcCtD
Cladribine—Cough—Doxorubicin—sarcoma	0.000146	0.000433	CcSEcCtD
Cladribine—Nervous system disorder—Epirubicin—sarcoma	0.000144	0.00043	CcSEcCtD
Cladribine—Thrombocytopenia—Epirubicin—sarcoma	0.000144	0.000429	CcSEcCtD
Cladribine—Tachycardia—Epirubicin—sarcoma	0.000144	0.000428	CcSEcCtD
Cladribine—Skin disorder—Epirubicin—sarcoma	0.000143	0.000426	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000142	0.00182	CbGpPWpGaD
Cladribine—Hyperhidrosis—Epirubicin—sarcoma	0.000142	0.000423	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—sarcoma	0.000142	0.000423	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—sarcoma	0.000142	0.000423	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—sarcoma	0.000142	0.000423	CcSEcCtD
Cladribine—Anxiety—Doxorubicin—sarcoma	0.000142	0.000421	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000141	0.00042	CcSEcCtD
Cladribine—Discomfort—Doxorubicin—sarcoma	0.00014	0.000418	CcSEcCtD
Cladribine—Anorexia—Epirubicin—sarcoma	0.00014	0.000418	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.00014	0.00178	CbGpPWpGaD
Cladribine—POLA1—S Phase—MYC—sarcoma	0.000139	0.00177	CbGpPWpGaD
Cladribine—Hypotension—Epirubicin—sarcoma	0.000138	0.000409	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—sarcoma	0.000137	0.000409	CcSEcCtD
Cladribine—Oedema—Doxorubicin—sarcoma	0.000136	0.000405	CcSEcCtD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—sarcoma	0.000136	0.00173	CbGpPWpGaD
Cladribine—Infection—Doxorubicin—sarcoma	0.000135	0.000403	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000134	0.000399	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—sarcoma	0.000134	0.000398	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—sarcoma	0.000133	0.000397	CcSEcCtD
Cladribine—Insomnia—Epirubicin—sarcoma	0.000133	0.000396	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—sarcoma	0.000133	0.000396	CcSEcCtD
Cladribine—Skin disorder—Doxorubicin—sarcoma	0.000132	0.000394	CcSEcCtD
Cladribine—Paraesthesia—Epirubicin—sarcoma	0.000132	0.000393	CcSEcCtD
Cladribine—POLE2—Cell Cycle—MDM2—sarcoma	0.000132	0.00168	CbGpPWpGaD
Cladribine—Hyperhidrosis—Doxorubicin—sarcoma	0.000132	0.000392	CcSEcCtD
Cladribine—Dyspnoea—Epirubicin—sarcoma	0.000131	0.000391	CcSEcCtD
Cladribine—Somnolence—Epirubicin—sarcoma	0.000131	0.000389	CcSEcCtD
Cladribine—Anorexia—Doxorubicin—sarcoma	0.00013	0.000386	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—CTNNB1—sarcoma	0.00013	0.00165	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—MYC—sarcoma	0.000129	0.00164	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CCND1—sarcoma	0.000128	0.00164	CbGpPWpGaD
Cladribine—Decreased appetite—Epirubicin—sarcoma	0.000128	0.000381	CcSEcCtD
Cladribine—RRM1—Metabolism—ENO2—sarcoma	0.000128	0.00163	CbGpPWpGaD
Cladribine—Hypotension—Doxorubicin—sarcoma	0.000127	0.000379	CcSEcCtD
Cladribine—Gastrointestinal disorder—Epirubicin—sarcoma	0.000127	0.000378	CcSEcCtD
Cladribine—RRM1—Metabolism—HBA1—sarcoma	0.000127	0.00162	CbGpPWpGaD
Cladribine—Fatigue—Epirubicin—sarcoma	0.000127	0.000378	CcSEcCtD
Cladribine—Constipation—Epirubicin—sarcoma	0.000126	0.000375	CcSEcCtD
Cladribine—Pain—Epirubicin—sarcoma	0.000126	0.000375	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000124	0.000369	CcSEcCtD
Cladribine—Insomnia—Doxorubicin—sarcoma	0.000123	0.000367	CcSEcCtD
Cladribine—Paraesthesia—Doxorubicin—sarcoma	0.000122	0.000364	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000122	0.00155	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000121	0.00155	CbGpPWpGaD
Cladribine—Dyspnoea—Doxorubicin—sarcoma	0.000121	0.000361	CcSEcCtD
Cladribine—Feeling abnormal—Epirubicin—sarcoma	0.000121	0.000361	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—sarcoma	0.000121	0.00036	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000121	0.00154	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Epirubicin—sarcoma	0.00012	0.000358	CcSEcCtD
Cladribine—Decreased appetite—Doxorubicin—sarcoma	0.000118	0.000352	CcSEcCtD
Cladribine—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000118	0.00035	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—sarcoma	0.000117	0.000349	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—SRC—sarcoma	0.000117	0.00149	CbGpPWpGaD
Cladribine—Urticaria—Epirubicin—sarcoma	0.000117	0.000348	CcSEcCtD
Cladribine—Pain—Doxorubicin—sarcoma	0.000116	0.000347	CcSEcCtD
Cladribine—Constipation—Doxorubicin—sarcoma	0.000116	0.000347	CcSEcCtD
Cladribine—Body temperature increased—Epirubicin—sarcoma	0.000116	0.000346	CcSEcCtD
Cladribine—Abdominal pain—Epirubicin—sarcoma	0.000116	0.000346	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CCND1—sarcoma	0.000115	0.00146	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—VEGFA—sarcoma	0.000114	0.00145	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—NRAS—sarcoma	0.000113	0.00144	CbGpPWpGaD
Cladribine—Feeling abnormal—Doxorubicin—sarcoma	0.000112	0.000334	CcSEcCtD
Cladribine—NR5A1—Generic Transcription Pathway—MYC—sarcoma	0.000111	0.00142	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Doxorubicin—sarcoma	0.000111	0.000331	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000109	0.00139	CbGpPWpGaD
Cladribine—Hypersensitivity—Epirubicin—sarcoma	0.000108	0.000323	CcSEcCtD
Cladribine—RRM1—Metabolism—PLCG1—sarcoma	0.000108	0.00138	CbGpPWpGaD
Cladribine—Urticaria—Doxorubicin—sarcoma	0.000108	0.000322	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—sarcoma	0.000108	0.00032	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—sarcoma	0.000108	0.00032	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000106	0.00135	CbGpPWpGaD
Cladribine—Asthenia—Epirubicin—sarcoma	0.000106	0.000314	CcSEcCtD
Cladribine—RRM2—Metabolism—ENO2—sarcoma	0.000105	0.00134	CbGpPWpGaD
Cladribine—RRM2—Metabolism—HBA1—sarcoma	0.000105	0.00133	CbGpPWpGaD
Cladribine—Pruritus—Epirubicin—sarcoma	0.000104	0.00031	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—MYC—sarcoma	0.000103	0.00131	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EGFR—sarcoma	0.000103	0.00131	CbGpPWpGaD
Cladribine—Diarrhoea—Epirubicin—sarcoma	0.000101	0.0003	CcSEcCtD
Cladribine—Hypersensitivity—Doxorubicin—sarcoma	0.0001	0.000299	CcSEcCtD
Cladribine—DCK—Metabolism—ENO2—sarcoma	9.83e-05	0.00125	CbGpPWpGaD
Cladribine—Asthenia—Doxorubicin—sarcoma	9.77e-05	0.000291	CcSEcCtD
Cladribine—DCK—Metabolism—HBA1—sarcoma	9.77e-05	0.00125	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	9.77e-05	0.00124	CbGpPWpGaD
Cladribine—Dizziness—Epirubicin—sarcoma	9.73e-05	0.00029	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—KRAS—sarcoma	9.69e-05	0.00124	CbGpPWpGaD
Cladribine—Pruritus—Doxorubicin—sarcoma	9.63e-05	0.000287	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	9.55e-05	0.00122	CbGpPWpGaD
Cladribine—Vomiting—Epirubicin—sarcoma	9.36e-05	0.000279	CcSEcCtD
Cladribine—Diarrhoea—Doxorubicin—sarcoma	9.32e-05	0.000277	CcSEcCtD
Cladribine—Rash—Epirubicin—sarcoma	9.28e-05	0.000276	CcSEcCtD
Cladribine—Dermatitis—Epirubicin—sarcoma	9.27e-05	0.000276	CcSEcCtD
Cladribine—Headache—Epirubicin—sarcoma	9.22e-05	0.000274	CcSEcCtD
Cladribine—POLE2—Cell Cycle—MYC—sarcoma	9.21e-05	0.00117	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	9.02e-05	0.00115	CbGpPWpGaD
Cladribine—Dizziness—Doxorubicin—sarcoma	9e-05	0.000268	CcSEcCtD
Cladribine—RRM2—Metabolism—PLCG1—sarcoma	8.92e-05	0.00114	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MDM2—sarcoma	8.85e-05	0.00113	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—CREB1—sarcoma	8.81e-05	0.00112	CbGpPWpGaD
Cladribine—Nausea—Epirubicin—sarcoma	8.74e-05	0.00026	CcSEcCtD
Cladribine—Vomiting—Doxorubicin—sarcoma	8.66e-05	0.000258	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—CCND1—sarcoma	8.62e-05	0.0011	CbGpPWpGaD
Cladribine—Rash—Doxorubicin—sarcoma	8.59e-05	0.000256	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—sarcoma	8.58e-05	0.000255	CcSEcCtD
Cladribine—Headache—Doxorubicin—sarcoma	8.53e-05	0.000254	CcSEcCtD
Cladribine—POLE—Cell Cycle—MDM2—sarcoma	8.49e-05	0.00108	CbGpPWpGaD
Cladribine—DCK—Metabolism—PLCG1—sarcoma	8.34e-05	0.00106	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CCND1—sarcoma	8.27e-05	0.00105	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—HRAS—sarcoma	8.24e-05	0.00105	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—CREB1—sarcoma	8.21e-05	0.00105	CbGpPWpGaD
Cladribine—Nausea—Doxorubicin—sarcoma	8.09e-05	0.000241	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	8.02e-05	0.00102	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CCND1—sarcoma	7.7e-05	0.000982	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—sarcoma	7.56e-05	0.000964	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CCND1—sarcoma	7.4e-05	0.000943	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—MDM2—sarcoma	7.29e-05	0.000929	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MYC—sarcoma	6.91e-05	0.000881	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—MDM2—sarcoma	6.79e-05	0.000866	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—CREB1—sarcoma	6.75e-05	0.000861	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MYC—sarcoma	6.63e-05	0.000846	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—CREB1—sarcoma	6.29e-05	0.000802	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MYC—sarcoma	6.18e-05	0.000788	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MDM2—sarcoma	6.05e-05	0.000771	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MYC—sarcoma	5.93e-05	0.000756	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND1—sarcoma	5.89e-05	0.000751	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—MDM2—sarcoma	5.59e-05	0.000712	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—sarcoma	5.37e-05	0.000684	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—sarcoma	5.27e-05	0.000672	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—MDM2—sarcoma	5.21e-05	0.000664	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—sarcoma	5.08e-05	0.000647	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—sarcoma	4.87e-05	0.000621	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—sarcoma	4.73e-05	0.000603	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—sarcoma	4.23e-05	0.000539	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—sarcoma	4e-05	0.00051	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ENO2—sarcoma	3.93e-05	0.000501	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—HBA1—sarcoma	3.91e-05	0.000498	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ENO2—sarcoma	3.89e-05	0.000496	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HBA1—sarcoma	3.87e-05	0.000493	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—sarcoma	3.73e-05	0.000475	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ENO2—sarcoma	3.63e-05	0.000463	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HBA1—sarcoma	3.61e-05	0.00046	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—sarcoma	3.47e-05	0.000443	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PLCG1—sarcoma	3.34e-05	0.000425	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PLCG1—sarcoma	3.3e-05	0.000421	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PLCG1—sarcoma	3.08e-05	0.000392	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—sarcoma	3.06e-05	0.000391	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—sarcoma	2.86e-05	0.000364	CbGpPWpGaD
